Literature DB >> 11945065

Cytotoxic immune response blunts long-term transgene expression after efficient retroviral-mediated hepatic gene transfer in rat.

Dominique Aubert1, Séverine Ménoret, Estelle Chiari, Virginie Pichard, Sophie Durand, Laurent Tesson, Philippe Moullier, Ignacio Anegon, Nicolas Ferry.   

Abstract

Vectors derived from oncoretroviruses can transduce a small proportion of hepatocytes when injected in the regenerating liver. Transgene expression may be sustained for months without immune response. In striking contrast, we observed a rapid extinction when the intravenous injection of a high input of nuclear beta-galactosidase (beta-gal) expression vector, one day after partial hepatectomy, led to a significant proportion of transduced cells in the liver. Extinction was associated with liver inflammation on tissue sections and appearance of antibodies against the transgene product, while vector genomes became undetectable in liver tissue by PCR. These observations suggested the elimination of transduced cells by an immune response. Transgenic rats tolerant for cytoplasmic beta-gal, or normal rats depleted in CD8 T lymphocytes, steadily expressed the beta-gal vector. In the spleen of normal rats, we detected cytotoxic cells directed against cells expressing beta-gal after the injection of the beta-gal vector. In jaundiced Gunn rats deficient in bilirubin glucuronosyl transferase (BGT1) and treated with a human BGT1 cDNA expression vector, we observed the same kinetics of extinction as well as the appearance of anti-BGT1 antibodies. This study demonstrates that retrovirus-mediated gene transfer may induce cytotoxic T lymphocytes specifically directed against transgene-expressing cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11945065     DOI: 10.1006/mthe.2002.0561

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  10 in total

1.  AAV gene transfer to the retina does not protect retrovirally transduced hepatocytes from the immune response.

Authors:  Marta Bellodi-Privato; Guylène Le Meur; Dominique Aubert; Alexandra Mendes-Madera; Virginie Pichard; Fabienne Rolling; Nicolas Ferry
Journal:  J Mol Med (Berl)       Date:  2004-03-24       Impact factor: 4.599

2.  Developing cell therapy techniques for respiratory disease: intratracheal delivery of genetically engineered stem cells in a murine model of airway injury.

Authors:  Anne-Laure Leblond; Patrice Naud; Virginie Forest; Clothilde Gourden; Christine Sagan; Bénédicte Romefort; Eva Mathieu; Bruno Delorme; Christine Collin; Jean-Christophe Pagès; Luc Sensebé; Bruno Pitard; Patricia Lemarchand
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

3.  Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles.

Authors:  D Sharma; R Al-Khalidi; S Edgar; Q An; Y Wang; C Young; D Nowis; D C Gorecki
Journal:  Gene Ther       Date:  2016-12-22       Impact factor: 5.250

4.  Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector.

Authors:  Gabriele Toietta; Viraj P Mane; Wilma S Norona; Milton J Finegold; Philip Ng; Antony F McDonagh; Arthur L Beaudet; Brendan Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 5.  Hepatic gene transfer as a means of tolerance induction to transgene products.

Authors:  Paul A LoDuca; Brad E Hoffman; Roland W Herzog
Journal:  Curr Gene Ther       Date:  2009-04       Impact factor: 4.391

Review 6.  Epigenetics and microRNAs in UGT1As.

Authors:  Cui-Lan Meng; Wei Zhao; Dan-Ni Zhong
Journal:  Hum Genomics       Date:  2021-05-25       Impact factor: 4.639

7.  Direct in vivo cell lineage analysis in the retrorsine and 2AAF models of liver injury after genetic labeling in adult and newborn rats.

Authors:  Virginie Pichard; Dominique Aubert; Nicolas Ferry
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

Review 8.  Gene therapy for severe combined immunodeficiency: are we there yet?

Authors:  Marina Cavazzana-Calvo; Alain Fischer
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

Review 9.  Novel vectors and approaches for gene therapy in liver diseases.

Authors:  Sheila Maestro; Nicholas D Weber; Nerea Zabaleta; Rafael Aldabe; Gloria Gonzalez-Aseguinolaza
Journal:  JHEP Rep       Date:  2021-04-30

10.  Specific micro RNA-regulated TetR-KRAB transcriptional control of transgene expression in viral vector-transduced cells.

Authors:  Virginie Pichard; Dominique Aubert; Sebastien Boni; Severine Battaglia; Dejana Ivacik; Tuan Huy Nguyen; Patrick Arbuthnot; Nicolas Ferry
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.